EP12.03. Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Michelle Dean
Meta Tag
Speaker Michelle Dean
Topic Metastatic NSCLC: Targeted Therapy - Other
Canadian healthcare system
non-small cell lung cancer
targeted therapy
adverse events
tyrosine kinase inhibitors
immune checkpoint inhibitors
oncogenic driver mutations
Glans-Look Lung Cancer Research program database
Powered By